254 related articles for article (PubMed ID: 20175776)
1. Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme.
Miners JS; van Helmond Z; Kehoe PG; Love S
Brain Pathol; 2010 Jul; 20(4):794-802. PubMed ID: 20175776
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of insoluble amyloid-β in down's syndrome is associated with increased BACE-1 and neprilysin activities.
Miners JS; Morris S; Love S; Kehoe PG
J Alzheimers Dis; 2011; 23(1):101-8. PubMed ID: 20930275
[TBL] [Abstract][Full Text] [Related]
3. Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-β.
Tayler H; Fraser T; Miners JS; Kehoe PG; Love S
J Alzheimers Dis; 2010; 22(4):1363-73. PubMed ID: 20930272
[TBL] [Abstract][Full Text] [Related]
4. Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-β (Aβ) Plaque Load and Aβ-Synthesizing and Aβ-Degrading Enzymes in Frontal Cortex.
Ashby EL; Miners JS; Kehoe PG; Love S
J Alzheimers Dis; 2016; 50(4):1191-203. PubMed ID: 26836178
[TBL] [Abstract][Full Text] [Related]
5. Effect of Global Brain Ischemia on Amyloid Precursor Protein Metabolism and Expression of Amyloid-Degrading Enzymes in Rat Cortex: Role in Pathogenesis of Alzheimer's Disease.
Babusikova E; Dobrota D; Turner AJ; Nalivaeva NN
Biochemistry (Mosc); 2021 Jun; 86(6):680-692. PubMed ID: 34225591
[TBL] [Abstract][Full Text] [Related]
6. Design of Peptide Substrate for Sensitively and Specifically Detecting Two Aβ-Degrading Enzymes: Neprilysin and Angiotensin-Converting Enzyme.
Chen PT; Chen CL; Lin LT; Lo CH; Hu CJ; Chen RP; Wang SS
PLoS One; 2016; 11(4):e0153360. PubMed ID: 27096746
[TBL] [Abstract][Full Text] [Related]
7. Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity.
Miners JS; Baig S; Tayler H; Kehoe PG; Love S
J Neuropathol Exp Neurol; 2009 Aug; 68(8):902-14. PubMed ID: 19606063
[TBL] [Abstract][Full Text] [Related]
8. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain.
Wang S; Wang R; Chen L; Bennett DA; Dickson DW; Wang DS
J Neurochem; 2010 Oct; 115(1):47-57. PubMed ID: 20663017
[TBL] [Abstract][Full Text] [Related]
9. Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications.
Jha NK; Jha SK; Kumar D; Kejriwal N; Sharma R; Ambasta RK; Kumar P
J Alzheimers Dis; 2015; 48(4):891-917. PubMed ID: 26444774
[TBL] [Abstract][Full Text] [Related]
10. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders.
Caccamo A; Oddo S; Sugarman MC; Akbari Y; LaFerla FM
Neurobiol Aging; 2005 May; 26(5):645-54. PubMed ID: 15708439
[TBL] [Abstract][Full Text] [Related]
11. Aβ-degrading enzymes: potential for treatment of Alzheimer disease.
Miners JS; Barua N; Kehoe PG; Gill S; Love S
J Neuropathol Exp Neurol; 2011 Nov; 70(11):944-59. PubMed ID: 22002425
[TBL] [Abstract][Full Text] [Related]
12. GEPT extract reduces Abeta deposition by regulating the balance between production and degradation of Abeta in APPV717I transgenic mice.
Tian J; Shi J; Zhang L; Yin J; Hu Q; Xu Y; Sheng S; Wang P; Ren Y; Wang R; Wang Y
Curr Alzheimer Res; 2009 Apr; 6(2):118-31. PubMed ID: 19355846
[TBL] [Abstract][Full Text] [Related]
13. New Insights into Epigenetic and Pharmacological Regulation of Amyloid-Degrading Enzymes.
Nalivaeva NN; Belyaev ND; Turner AJ
Neurochem Res; 2016 Mar; 41(3):620-30. PubMed ID: 26376806
[TBL] [Abstract][Full Text] [Related]
14. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention.
Eckman EA; Eckman CB
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1101-5. PubMed ID: 16246055
[TBL] [Abstract][Full Text] [Related]
15. Insulin-signaling Pathway Regulates the Degradation of Amyloid β-protein via Astrocytes.
Yamamoto N; Ishikuro R; Tanida M; Suzuki K; Ikeda-Matsuo Y; Sobue K
Neuroscience; 2018 Aug; 385():227-236. PubMed ID: 29932983
[TBL] [Abstract][Full Text] [Related]
16. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease.
Nalivaeva NN; Fisk LR; Belyaev ND; Turner AJ
Curr Alzheimer Res; 2008 Apr; 5(2):212-24. PubMed ID: 18393806
[TBL] [Abstract][Full Text] [Related]
17. Beta-amyloid secretases and beta-amloid degrading enzyme expression in lens.
Li G; Percontino L; Sun Q; Qazi AS; Frederikse PH
Mol Vis; 2003 May; 9():179-83. PubMed ID: 12740567
[TBL] [Abstract][Full Text] [Related]
18. Impaired performance of female APP/PS1 mice in the Morris water maze is coupled with increased Aβ accumulation and microglial activation.
Gallagher JJ; Minogue AM; Lynch MA
Neurodegener Dis; 2013; 11(1):33-41. PubMed ID: 22627185
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme as a potential target for treatment of Alzheimer's disease: inhibition or activation?
Zou K; Michikawa M
Rev Neurosci; 2008; 19(4-5):203-12. PubMed ID: 19145983
[TBL] [Abstract][Full Text] [Related]
20. Powering Amyloid Beta Degrading Enzymes: A Possible Therapy for Alzheimer's Disease.
Sikanyika NL; Parkington HC; Smith AI; Kuruppu S
Neurochem Res; 2019 Jun; 44(6):1289-1296. PubMed ID: 30806879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
